Value-based contracts — big talk, big deal, or real deal?
Pharmaceutical companies guaranteeing results and paying for failures?
Payers paying more if a cancer patient has a shorter lifespan on a specific drug?
Pharma guaranteeing the control of cholesterol?
A few years ago, these seemed as unlikely as a biosimilar version of a blockbuster biologic. Now value-based contracting (VBC) seems to be the hottest topic in payer-pharmaceutical company relationships.l?